Context: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events. Objective: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Data Sources: We searched MEDLINE, Embase, Web of Science, and CENTRAL from July 31, 2019 to February 8, 2020. Study Selection: Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. Data Extraction: Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE). Data Synthesis: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76–1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48–2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusions: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.
Key Points: The effect of sodium-glucose cotransporter 2 inhibitors in preventing kidney outcomes in populations at lower risk of kidney disease remains uncertain. Pooled data from randomized controlled trials show that sodium-glucose cotransporter 2 inhibitors prevent kidney outcomes across the spectrum of kidney disease risk. Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with CKD at high risk of adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remains uncertain. We aim to evaluate the effect of SGLT2 inhibitors on kidney outcomes across the Kidney Disease Improving Global Outcomes (KDIGO) classification and urinary albumin-creatinine ratio (UACR) levels. Methods: We have searched medical literature analysis and retrieval system online (PubMed), excerpta medica database, and Cochrane Central Register of Controlled Trials from inception up to August 8, 2023. In pairs, researchers selected large (≥500 participants per arm) randomized placebo-controlled trials of SGLT2 inhibitors, with a minimum duration of 1 year. Researchers independently extracted study-level data and assessed within-study risk of bias with the risk of bias 2.0 tool and quality of evidence with grading of recommendations, assessment, development and evaluation. Results: We included ten trials, encompassing 78,184 participants and a median follow-up of 2.7 years. Risk of bias was overall low. We performed meta-analyses summarizing individual study hazard ratios (HRs) and 95% confidence intervals (CIs) using a random-effects model. SGLT2 inhibitors reduced the composite kidney outcome across all KDIGO (HR [95% CI]: low 0.48 [0.32 to 0.71], moderate 0.60 [0.39 to 0.93], high 0.59 [0.47 to 0.74], very high 0.59 [0.49 to 0.72]) and UACR (HR [95% CI]: 300 mg/g 0.61 [0.52 to 0.73]) groups, without evidence of heterogeneity between groups. A small proportion of participants without diabetes in low-risk groups were referred, and there was lack of standardization of composite outcomes. Conclusions: SGLT2 inhibitors consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels. Clinical Trial registry name and registration number: CRD42023492877.
23 February 2024 in Diabetes, Obesity and Metabolism